Har skjedd noe her siden July 7, 2016:


Pfizer Drug Cocktail
In the meantime, drugmakers are moving ahead to capitalize on the findings. Pfizer Inc. plans to combine a checkpoint inhibitor with two drugs in development that stimulate the immune system. The goal is to assess whether the three-drug cocktail works on a variety of tumor types for patients with a high mutational burden.

Pfizer hypothesizes that by adding drugs that stimulate the immune system, the combination will help the “survival” of immune cells, which typically “get exhausted after a while,” said Chris Boshoff, head of the company’s immuno-oncology program.

Regulators are also paying attention. The U.S. Food and Drug Administration’s acting director of the Oncology Center of Excellence, Richard Pazdur, said the mutational-load findings are a significant discovery.

“I look at it from a patient’s point of view,” he said, recalling data from refractory bile duct cancer patients. “It was a small number of patients, but it was a very high number of patients that had a response, and I was thinking ‘Everybody who has this disease should get tested for what their MSI status is.’”

https://www.bloomberg.com/news/articles/2016-07-07/more-cancer-mutations-may-be-good-for-immunotherapy-patients